Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Lilly’s retatrutide shows 28% weight loss, but increased side effects (opens in a new tab)

drugdiscoverytrends.com · 2026-05-28

Short answerEvidenceSource

Short answer

Not supported

Not supported.

3 key claims are not backed by the study. 3 other points were not covered by the paper.

  • 3 not supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Three claims aren't supported by the study. Three claims the study doesn't address.

  • 3 not supported
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not supportedEli Lilly’s retatrutide, a triple hormone receptor agonist, demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials.View evidenceHide evidence

As stated28.3% over 80 weeks

Why this verdict

The abstract-level paper profile supports that retatrutide is a triple-receptor agonist tested in a phase 3 randomized trial over 80 weeks and produced large weight loss at the highest 12-mg dose. However, the magnitude in the profile is mean percent body-weight change of -25.0% at 80 weeks for 12 mg versus -3.9% with placebo, not 28.3%. The headline-prominence 28.3% figure therefore outruns the supplied paper evidence.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Claim 2 of 6Not supportedThe article says direct body composition data for retatrutide have not been published, but it estimates that the reported weight loss could translate into approximately 14 to 24.6 pounds of muscle mass loss.View evidenceHide evidence

As stated14 to 24.6 lbs

Why this verdict

The paper profile contains body-weight outcomes but does not report body-composition, lean-mass, or muscle-loss data, nor does it provide or support the article’s estimated 14 to 24.6 pounds of muscle mass loss. The story’s caveat that direct body-composition data are unavailable is directionally cautious, but the numerical muscle-loss estimate is not supported by the supplied paper profile.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Claim 3 of 6Not supportedThe article says the effect of retatrutide on bone density is not yet known and cites other GLP-1-related evidence suggesting weight loss can reduce bone density, with a possible protective role for GIP signaling.View evidenceHide evidence

Why this verdict

The abstract-level paper profile does not address bone density, bone loss, or a protective role of GIP signaling. Those points may come from other literature or speculation, but they are not supported by the supplied profile of this paper.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Claim 4 of 6Not coveredThe medicine comes with increased severity of side effects compared with other GLP-1 drugs.View evidenceHide evidence

Why this verdict

The abstract reports only that gastrointestinal adverse events were the most common; it does not provide severity grading, detailed frequencies, serious adverse event rates, or a comparison with other GLP-1 drugs. The trial comparator in the profile is placebo, not semaglutide, tirzepatide, or other GLP-1 agents.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Claim 5 of 6Not coveredAt the highest dose, 11.3% of participants discontinued treatment due to adverse effects, which the article says is higher than tirzepatide, semaglutide, and orforglipron.View evidenceHide evidence

As stated11.3% discontinuation

Why this verdict

The abstract-level profile does not report adverse-event discontinuation rates, including the stated 11.3% at the highest dose. It also does not contain comparisons with tirzepatide, semaglutide, or orforglipron. Detailed safety/discontinuation data are explicitly listed as unavailable at abstract depth.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Claim 6 of 6Not coveredApproximately 12.5% of participants on the highest dose experienced dysesthesia, described as burning, tingling, or pins-and-needles sensations, and these events were generally mild to moderate and mostly resolved during treatment.View evidenceHide evidence

As stated12.5%

Why this verdict

The supplied abstract profile does not mention dysesthesia, its frequency, severity, or resolution during treatment. It only states that gastrointestinal adverse events were the most common, without detailed adverse-event tables.

1

Study evidence

Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).

“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Core trial design: TRIUMPH-1 was a phase 3 randomized, double-blind, placebo-controlled trial in 2339 adults with obesity without diabetes, testing once-weekly retatrutide 4 mg, 9 mg, and 12 mg versus placebo for 80 weeks.

    The story reflects the phase 3 and 80-week retatrutide context, but it omits key interpretation-shaping details: randomized double-blind placebo-controlled design, placebo comparator, sample size, and the population restriction to adults with obesity without diabetes.

    From Phase 3 randomized double-blind placebo-controlled trial (parallel groups)

  • Primary weight finding: at 80 weeks, mean percent body-weight change was -17.6% with 4 mg, -23.7% with 9 mg, -25.0% with 12 mg, and -3.9% with placebo; primary comparisons for 9 mg and 12 mg versus placebo were statistically significant.

    The story captures large weight loss but gives a highest-dose value of 28.3%, whereas the supplied abstract profile reports -25.0% for the 12-mg dose under the treatment-regimen/ITT estimand.

    From Phase 3 randomized double-blind placebo-controlled trial (parallel groups)

  • Safety finding available at abstract depth: gastrointestinal adverse events were the most common adverse events; the abstract does not provide detailed frequencies, severity grading, serious adverse-event rates, or discontinuation rates.

    The story mentions nausea and vomiting, consistent with a gastrointestinal tolerability theme, but it presents more granular safety claims and cross-drug severity comparisons that are not available in the abstract profile. The abstract-depth limitation on detailed safety data is not acknowledged.

    From Phase 3 randomized double-blind placebo-controlled trial (parallel groups)

  • Important limitation: the abstract profile lacks detailed methodological and safety data, including adverse-event frequencies/severity, discontinuations, adherence, confidence intervals, and missing-data details beyond the stated estimand.

    The story’s caveats focus on body composition, dysesthesia mechanism, and bone density. It does not acknowledge that, at abstract depth, the paper profile itself does not substantiate the detailed tolerability and discontinuation claims.

    From Phase 3 randomized double-blind placebo-controlled trial (parallel groups)

  • Prespecified knee osteoarthritis subgroup: among participants with knee osteoarthritis, retatrutide reduced WOMAC pain scores more than placebo, with statistically significant 9-mg and 12-mg comparisons.

    This is a secondary contribution in the paper profile, but it is not covered in the presented story.

    From Randomized double-blind phase 3 trial; prespecified knee osteoarthritis subgroup analysis

  • Prespecified obstructive sleep apnea subgroup: among participants with obstructive sleep apnea, retatrutide reduced apnea–hypopnea index more than placebo, with statistically significant 9-mg and 12-mg comparisons.

    This is another secondary contribution in the paper profile, but it is not covered in the presented story.

    From Phase 3 randomized double-blind trial, prespecified OSA subgroup analysis

  • Estimand and comparison structure: weight-related endpoints used a treatment-regimen/ITT estimand, and the primary comparisons were 9 mg and 12 mg versus placebo.

    The story states an average highest-dose weight-loss magnitude but does not identify the ITT/treatment-regimen estimand or the placebo-referenced primary comparison structure, both of which are material to interpreting the reported effect.

    From Phase 3 randomized double-blind placebo-controlled trial (parallel groups)

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate the efficacy and safety of once-weekly retatrutide (4 mg, 9 mg, 12 mg) vs placebo over 80 weeks for weight loss in adults with obesity without diabetes.Phase 3 randomized double-blind placebo-controlled trial (parallel groups)Expand

In plain English

Phase 3 randomized, double-blind, placebo-controlled trial (TRIUMPH-1) in 2339 adults with obesity without diabetes comparing once-weekly subcutaneous retatrutide (4, 9, 12 mg) versus placebo for 80 weeks. Primary efficacy outcome was percent change in body weight (primary comparisons: 9 mg and 12 mg vs placebo) analyzed with a treatment-regimen (ITT) estimand. Retatrutide produced large, dose-related mean percent weight reductions vs placebo at 80 weeks; gastrointestinal events were the most common adverse events reported.

Key findings

  • Retatrutide produced large, dose-related mean percent reductions in body weight at 80 weeks compared with placebo.Mean percent change in body weight at 80 weeks: -17.6% (4 mg), -23.7% (9 mg), -25.0% (12 mg) vs -3.9% (placebo); differences for primary comparisons: 9 mg vs placebo -19.8 percentage points (P<0.001), 12 mg vs placebo -21.0 percentage points (P<0.001).
  • Safety: the most common adverse events reported in the trial were gastrointestinal.
“In this phase 3, randomized, double-blind trial, we assigned adults with obesity without diabetes to receive a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2human in vivoEvaluate retatrutide’s effect on knee osteoarthritis symptoms (WOMAC pain score) in the prespecified subgroup of participants with knee osteoarthritis.Randomized double-blind phase 3 trial; prespecified knee osteoarthritis subgroup analysisExpand

In plain English

Prespecified subgroup analysis (n=574) of the randomized, double-blind phase 3 TRIUMPH-1 trial evaluated change in WOMAC pain score (1–10) over 80 weeks in participants with knee osteoarthritis. A hybrid-treatment estimand (hypothetical strategy treating intercurrent events as treatment failure) was prespecified for this subgroup endpoint, with ITT analyses also reported. Retatrutide produced larger mean reductions in WOMAC pain than placebo across doses; primary between-group comparisons reported for the 9‑mg and 12‑mg doses vs. placebo were statistically significant (P<0.001).

Key findings

  • In the prespecified knee osteoarthritis subgroup (n=574), retatrutide produced larger mean reductions in WOMAC pain than placebo by both the hybrid-treatment estimand and ITT analyses; primary between-group comparisons for 9 mg and 12 mg versus placebo were statistically significant (P<0.001).Hybrid estimand: mean change –3.2 (4 mg), –3.5 (9 mg), –3.6 (12 mg) vs –1.9 (placebo); between-group differences for 9 mg and 12 mg vs placebo: –1.6 and –1.8 points (both P<0.001). ITT: mean change –3.4 (4 mg), –3.9 (9 mg), –4.1 (12 mg) vs –2.5 (placebo); between-group differences for 9 mg and 12 mg vs placebo: –1.4 and –1.6 points (both P<0.001).
“...the change in the WOMAC pain score ... in the subgroup of 574 participants with knee osteoarthritis”
What this piece can’t prove
  • Summary is based on abstract text only; the abstract does not provide subgroup baseline characteristics, variability measures (SDs or CIs), or full statistical-method details for the knee OA analysis.
  • Abstract lacks information on responder analyses, distribution of missing data in the subgroup, and exact handling/modeling of intercurrent events beyond the high-level estimand description.

1 further detail could not be confirmed from the summary.

3human in vivoEvaluate retatrutide’s effect on obstructive sleep apnea severity (apnea–hypopnea index) in the prespecified subgroup of participants with obstructive sleep apnea.Phase 3 randomized double-blind trial, prespecified OSA subgroup analysisExpand

In plain English

Prespecified subgroup analysis (n=243) from the phase 3 TRIUMPH-1 trial evaluated change in apnea–hypopnea index (AHI) over 80 weeks in participants with obstructive sleep apnea randomized to once-weekly subcutaneous retatrutide (4 mg, 9 mg, 12 mg) versus placebo. A hybrid-treatment estimand was prespecified for OSA endpoints (with ITT results reported in parallel). Retatrutide produced larger reductions in AHI than placebo; between-group differences for the 9-mg and 12-mg doses versus placebo were statistically significant (P<0.001).

Key findings

  • Retatrutide produced larger reductions in apnea–hypopnea index (events per hour) than placebo in the prespecified OSA subgroup.Hybrid-treatment estimand: between-group differences versus placebo for 9 mg and 12 mg were -24.4 and -21.9 events/hour, respectively (both P<0.001). ITT: differences -24.7 and -22.5 events/hour, respectively (both P<0.001).
“...the change in the apnea-hypopnea index in the 243 participants with obstructive sleep apnea.”
What this piece can’t prove
  • Abstract does not specify how OSA was defined or diagnosed (e.g., criteria, testing modality) nor the protocol for AHI measurement and scoring.
  • Abstract does not report subgroup-specific sample-size justification or power for the OSA endpoint.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

And 10 more candidates considered.